ArticleOpen forum infectious diseases2022
Clinical Impact of Ceftriaxone Resistance in
Open access · goldAbstract read
In one paragraph
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Occurrence of β-lactamases among Enterobacterales isolates from 22 US hospitals in a 10-year period: report from the International Network for Optimal Resistance Monitoring (INFORM) programme.JAC-antimicrobial resistance · 2026Article
- Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Trends and correlations of infection rates and drug resistance of Escherichia coli among ICU and Non-ICU patients in Guizhou, China.PloS one · 2026Article
- Extended-spectrum-β-lactamase-producing Gram-negative bacteria are associated with high mortality in children with bloodstream infections in Dar es Salaam, Tanzania.BMC infectious diseases · 2025Article
- Clinical Outcomes of Early Phenotype-Desirable Antimicrobial Therapy for Enterobacterales Bacteremia.JAMA network open · 2024Article
- Prevalence, antimicrobial resistance and detection of virulence genes of Escherichia coli and Salmonella spp. isolated from white-lipped peccaries and collared peccaries.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- The genotypic antibiogram: using gram-negative antimicrobial resistance genes identified via rapid blood culture identification tests to optimize treatment of Enterobacterales bloodstream infections.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 19 institutions in 2 countries.
Pranita D TammaDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-4143-6324
Lauren KomarowBiostatistics Center, George Washington University, Rockville, Maryland, USA.
Lizhao GeBiostatistics Center, George Washington University, Rockville, Maryland, USA.
Julia Garcia-DiazDepartment of Infectious Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana, USA.
Erica S HercDivision of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
Yohei DoiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-9620-2525
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Owen AlbinDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-1659-4902
Elie SaadeDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Loren G MillerDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA.
Jesse T JacobDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Michael J SatlinDivision of Infectious Diseases, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA.
Martin KrsakDivision of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0002-1746-7462
W Charles HuskinsDivision of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Sorabh DharDivision of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA.
Samuel A ShelburneDivision of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9721-263X
Carol HillDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Keri R BaumDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Minal BhojaniDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Kerryl E Greenwood-QuaintanceDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Suzannah M Schmidt-MalanDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-6344-4141
Scott R EvansBiostatistics Center, George Washington University, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0003-3186-172X
Henry F ChambersDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Vance G FowlerDivision of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0003-4784-3227
Antibacterial Resistance Leadership Group
Mayo Clinic · USClinical Research Institute · USGeorge Washington University · USDuke Medical Center · USEmory University · USFujita Health University · JPHenry Ford Hospital · USHouston Methodist · USJohns Hopkins University · USNewYork–Presbyterian Hospital · USOchsner Medical Center · USThe University of Texas MD Anderson Cancer Center · USUCLA Medical Center · USUniversity of California, San Francisco · USUniversity of Colorado Denver · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · USUniversity School · USWayne State University · US
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MProject 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2025
$12.0MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MNIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS UM1 AI104681
Abstract
Background: Ceftriaxone-resistant (CRO-R) Methods: This is a prospective cohort of patients with Results: Notable differences between patients infected with CRO-R and CRO-S Conclusions: Patients with CRO-R
Indexed as
bacteremiaceftriaxoneESBLEscherichia colimortalityresistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.